Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1998-08-06
2001-01-16
Elliott, George C. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S375000, C536S024500
Reexamination Certificate
active
06174870
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the inhibition of papillomavirus and the diagnosis and treatment of infections in animals caused by papillomavirus. This invention is also directed to the detection and quantitation of papillomavirus in samples suspected of containing it. Additionally. this invention is directed to oligonucleotides and oligonucleotide analogs which interfere with or modulate the function of messenger RNA from papillomavirus. Such interference can be employed as a means of diagnosis and treatment of papillomavirus infections. It can also form the basis for research reagents and for kits both for research and for diagnosis.
BACKGROUND OF THE INVENTION
The papillomaviruses (PV) are widespread in nature and are generally associated with benign epithelial and fibroepithelial lesions commonly referred to as warts. They have been detected in and isolated from a variety of higher vertebrates including human, cattle, rabbits, deer and several avian species. Although these viruses are generally associated with benign lesions, a specific subset of the viruses have been associated with lesions that may progress to carcinomas. The implication that these viruses may play a etiologic role in the development of some human cancers follows from numerous studies that have shown the presence of transcriptionally active human papillomavirus (HPV) deoxyribonucleic acids in a high percentage of certain cancerous lesions. Zur Hausen, H. and Schneider, A. 1987. In:
The Papovaviridae
, vol. 2, edited by N. P. Salzman and P. M. Howley, pp. 245-264. Plenum Press, New York.
In man, human papillomaviruses cause a variety of disease including common warts of the hands and feet, laryngeal warts and genital warts. More than 57 types of HPV have been identified so far. Each HPV type has a preferred anatomical site of infection; each virus can generally be associated with a specific lesion. Genital warts, also referred to as venereal warts and condylomata acuminata, are one of the most serious manifestations of PV infection. As reported by the Center for Disease Control, the sexual mode of transmission of genital warts is well established and the incidence of genital warts is on the increase. The seriousness of genital warts is underlined by the recent discovery that HPV DNA can be found in all grades of cervical intraepithelial neoplasia (CIN I-III) and that a specific subset of HPV types can be found in carcinoma in situ of the cervix. Consequently, women with genital warts, containing specific HPV types are now considered at high risk for the development of cervical cancer. Current treatments for genital warts are inadequate.
There is a great, but as yet unfulfilled, desire to provide compositions of matter which can interfere with papillomavirus. It is similarly desired to achieve methods of therapeutics and diagnostics for papillomavirus infections in animals. Additionally, improved kits and research reagents for use in the study of papillomavirus are needed.
OBJECTS OF THE INVENTION
It is an object of this invention to provide oligonucleotides and oligonucleotide analogs which are capable of hybridizing with messenger RNA of papillomavirus to inhibit the function of the messenger RNA.
It is a further object to provide oligonucleotides and analogs which can modulate the functional expression of papillomavirus DNA through antisense interaction with messenger RNA of the virus.
Yet another object of this invention is to provide methods of diagnostics and therapeutics for papillomavirus in animals.
Methods, materials and kits for detecting the presence or absence of papillomavirus in a sample suspected of containing it are further objects of the invention.
Novel oligonucleotides and oligonucleotide analogs are other objects of the invention.
These and other objects will become apparent to persons of ordinary skill in the art from a review of the instant specification and appended claims.
REFERENCES:
patent: 5681944 (1997-10-01), Crooke et al.
patent: 5811232 (1998-09-01), Crooke et al.
patent: 96/39501 (1996-12-01), None
Amtmann, E & Sauer, G., Bovine Papilloma Virus Transcription: Polyadenylated RNA Species and Assessment of the Direction of Transcription,J. Virol. 43, 59-66 (1982).
Androphy, E. J., et al., Bovine Papillomvarius E2 Trans-activiting Gene Product Binds to Specific Sites in Papillomvarius DNA,Nature325, 70-73 (1987).
Baker, C.C. & Howley, P.M. Differential Promoter Utilization by the Bovine Papillomavirus in Transformed Cells and Productively Infected Wart Tissues,EMBO J. 6, 1027-1035 (1987).
Berg, L.J., et al., Complementation of a Bovine Papilloma Virus Low-Copy-Number Mutant: Evidence for a Temporal Requirement of the Complementing Gene,Mol. Cell. Biol. 6, 859-869 (1986).
Boshart, M., et al., A New Type of Papillomavirus DNA, its Presence in Genital Cancer Biopsies and in Cell Lines Derived from Cervical Cancer,EMBO J. 3, 1151-1157 (1984).
Burnett, S., et al., Messenger RNAs from the E1 Region of Bovine Papillomavirus Type 1 Detected in Virus-Infected Bovine Cells,Nucleic Acids Res. 15, 8607-8620 (1987).
Chen, E.Y., et al., The Primary Structure and Genetic Organization of the Bovine Papillomavirus Type 1 Genome,Nature299, 529-534 (1982).
Chin, M.T., et al., Regulation of Human Papillomavirus Type 11 Enhancer and E6 Promoter by Activating and Repressing Proteins from the E2 Open Reading Frame: Functional and Biochemical Studies,J. Virol. 62, 2994-3002 (1988).
Cowsert, L. M., et al., Topographical and Conformational Epitopes of Bovine Papillomavirus Type 1 Defined by Monoclonal Antibodies,JNCI79:1053-1057 (1987).
Cowsert, L.M., et al., Identification of the Bovine Papillomavirus L1 Gene Product Using Monoclonal Antibodies,Virology165, 613-615 (1988).
Dahlberg, A. E., et al., Electrophoretic Characterization of Bacterial Polyribosomes in Agarose-Acrylamide Composite Gels,J. Mol. Biol. 41:39(1969).
Dartmann, K., et al., The Nucleotide Sequence and genome Organization of Human Papilloma Virus Type 11,Virology151:124-130 (1986).
DiMaio, D., Nonsense Mutation in Open Reading Frame E2 of Bovine Papillomavirus DNA,J. Virol. 57, 475-480 (1986).
DiMaio, D. & Settleman, J., Bovine Papillomavirus Mutant Termperature Sensitive for Transformation, Replication and Transactivation,EMBO J. 7, 1197-1204 (1988).
D{umlaut over (u)}rst, M., et al., A Papillomavirus DNA from a Cervical Carcinoma and Its Prevalence in Cancer Biopsy Samples from Different Geographic Regions,Proc. Natl. Acad. Sci. USA80, 3812-3815 (1983).
Dvoretzky, I. et al., A Quantitative in Vitro Focus Assay for Bovine Papilloma Virus,Virology103:369-375 (1980).
Engel, L.W., et al., Transcriptional Organization of Bovine Papillomavirus Type 1,J. Virol. 47, 516-528 (1983).
Frost, E. and Williams, J., Mapping Temperature-Sensitive and Host-Range Mutations of Adenovirus Type 5 by Marker Rescue,Virology91:39-50 (1978).
Gius, D., et al., Inducible and Consitutive Enahncer Domains in the Noncoding Region of Human Papillomavirus Type 18,J. Virol. 62, 665-672 (1988).
Graham, F. L. and van der Eb, A. J., A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,Virology52:456-461 (1973).
Gissmann, L., et al., Human Papillomavirus Types 6 and 11 DNA Sequences in Genital and Laryngeal Papillomas and in Some Cervical Cancers,Proc. Natl. Acad. Sci. USA80, 560-563 (1983).
Groff, D.E. & Lancaster, W.D., Genetic Analysis ofthe 3′ Early Region Transformation and Replication Functions of Bovine papillomavirus Type 1,Virology150, 221-230 (1986).
Heilman, C.A., et al., Virus-Specific Transcription in Bovine Papillomavirus-Transformed Mouse Cells,Virology119, 22-34 (1982).
Hirochika, H., et al., Enhancers and trans-Acting E2 Transcriptional Factors of Papillomaviruses,J. Virol. 61, 2599-2606 (1987).
Iyer, R. P., et al., The Automated Synthesis of Sulfur-Containing Oligodexoyribonucleotides Using 3H-1,2-Benzodithiol-3-one 1,1-Dioxide as a Sulfure-Transfer Reagent,J. Org. Chem. 55:4693-4699 (1990).
Lusky, M. & Botchan, M.R., Genetic Analysis of Bovine Papillomavirus Type 1 trans-Acting Replication Factors,J. Virol.
Cowsert Lex M.
Crooke Stanley T.
Ecker David J.
Mirabelli Christopher K.
Elliott George C.
ISIS Pharmaceuticals Inc.
Larson Thomas G.
Law Offices of Jane Massey Licata
LandOfFree
Antisense oligonucleotide inhibition of papillomavirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotide inhibition of papillomavirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotide inhibition of papillomavirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2541173